Source: Annual Congress 2010 - PG4 Core Curriculum Postgraduate Course: Pathology for the clinician



Rating:

Share or cite this content

Citations should be made in the following way:
E. Brambilla (Grenoble, France). Novel aspects in lung cancer pathology: how does it help for selecting chemotherapy?. Annual Congress 2010 - PG4 Core Curriculum Postgraduate Course: Pathology for the clinician

Member's Comments

No comment yet.

Related content which might interest you: Targeted therapies for lung cancer: how did the game begin? Source: Breathe 2016; 12: 177-179 Year: 2016 Novel approaches in metastasised non-small cell lung cancer with a special focus on modern systemic therapies Source: International Congress 2019 – State of the art session: Thoracic oncology Year: 2019 Second-line medical treatment for nonsmall cell lung cancer: what happens in reality Source: Annual Congress 2010 - Lung cancer progress after first-line therapy: which treatment makes sense and which does not? Year: 2010 Early stage nonsmall-cell lung cancer: therapeutic options (surgery, adjuvant and neoadjuvant therapy) Source: Annual Congress 2011 - PG10 Management of thoracic tumours in practice: a HERMES basic course Year: 2011 Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing? Source: Eur Respir J 2014; 44: 1011-1022 Year: 2014 New treatment concepts in stage IV non-small cell lung cancer: personalised multidisciplinary approaches Source: Virtual Congress 2021 – Thoracic oncology Year: 2021 Which gene expression signatures in pharmacogenomic strategies for lung cancer? Source: Annual Congress 2010 - Customised chemotherapy for lung cancer Year: 2010 PG1 Re-defining the role of chest physicians in lung cancer:ÿnew opportunities in diagnostics and therapy Source: Milan 2017 - Educational material Year: 2017 Marginal candidates for lung cancer surgery: is the consensus of real benefit? Source: Annual Congress 2010 - Selection criteria in lung cancer surgery: what really changed? Year: 2010 Induction chemotherapy before lung cancer resection: experiences and perspectives Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004 Diagnosing lung cancer: is the 28 day rule appropriate? Source: Eur Respir J 2004; 24: Suppl. 48, 298s Year: 2004 Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives Source: Eur Respir Rev 2011; 20: 45-52 Year: 2011 Stem cells and lung cancer treatment: any hope? Source: International Congress 2016 – Molecular footprints in lung cancer diagnosis and management Year: 2016 ALK- and ROS-1-inhibition: a relevant treatment strategy for lung cancer? Source: International Congress 2014 – Update on lung cancer biology for clinicians Year: 2014 Circulating fibrocytes as a new tool to predict lung cancer progression after surgery? Source: Eur Respir J, 58 (6) 2101221; 10.1183/13993003.01221-2021 Year: 2021